Welch Carly, Greig Carolyn, Masud Tahir, Wilson Daisy, Jackson Thomas A
1Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
2MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Birmingham and University of Nottingham, UK.
Aging Dis. 2020 Dec 1;11(6):1345-1351. doi: 10.14336/AD.2020.1014. eCollection 2020 Dec.
The COVID-19 pandemic has had a devastating global impact, with older adults being most at risk of death from the disease. However, acute sarcopenia occurs in survivors of COVID-19; older adults and the most critically unwell patients are the most at risk. Acute sarcopenia is an under-recognised condition of acute muscle insufficiency, defined by declines in muscle function and/or quantity within six months, usually following a stressor event. This commentary reviews definition and mechanisms of acute sarcopenia in COVID-19 and suggests recommendations for research and clinical practice. Research should now focus on the longer-term consequences of acute sarcopenia in patients who have suffered from COVID-19. At the same time, clinicians need to be increasingly aware of the condition, and measurements of muscle strength, quantity, and physical performance should be embedded into clinical practice. Clinicians should consider the risks of acute sarcopenia when weighing up the risks and benefits of treatment (e.g. dexamethasone), and instigate multidisciplinary treatment including dietetics input.
新冠疫情对全球造成了毁灭性影响，老年人死于该疾病的风险最高。然而，急性肌肉减少症在新冠幸存者中出现；老年人和病情最严重的患者风险最大。急性肌肉减少症是一种未得到充分认识的急性肌肉功能不全状况，通常在应激事件后六个月内，由肌肉功能和/或数量下降来定义。本评论综述了新冠疫情中急性肌肉减少症的定义和机制，并提出了研究和临床实践建议。现在研究应聚焦于新冠患者急性肌肉减少症的长期后果。与此同时，临床医生需要越来越多地了解这种情况，肌肉力量、数量和身体表现的测量应纳入临床实践。临床医生在权衡治疗（如地塞米松）的风险和益处时应考虑急性肌肉减少症的风险，并启动包括营养科参与的多学科治疗。
